Judith I. Tsui

ORCID: 0000-0003-0877-5399
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Opioid Use Disorder Treatment
  • HIV, Drug Use, Sexual Risk
  • Hepatitis C virus research
  • Substance Abuse Treatment and Outcomes
  • HIV/AIDS Research and Interventions
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Prenatal Substance Exposure Effects
  • Pain Management and Opioid Use
  • HIV-related health complications and treatments
  • Pharmacological Effects and Toxicity Studies
  • Alcohol Consumption and Health Effects
  • Digital Mental Health Interventions
  • Medication Adherence and Compliance
  • Health Policy Implementation Science
  • Mental Health Treatment and Access
  • Homelessness and Social Issues
  • Cannabis and Cannabinoid Research
  • Forensic Toxicology and Drug Analysis
  • Sex work and related issues
  • Treatment of Major Depression
  • Pain Mechanisms and Treatments
  • HIV/AIDS drug development and treatment
  • Mental Health and Patient Involvement
  • Neurological and metabolic disorders

Harborview Medical Center
2016-2025

University of Washington
2016-2025

University of California, San Francisco
2005-2024

Seattle University
2021-2024

Johns Hopkins University
2022-2024

Essays on Canadian Writing
2024

Albert Einstein College of Medicine
2024

Clemson University
2024

University of New Mexico
2024

Montefiore Medical Center
2024

Buprenorphine opioid agonist treatment (OAT) has established efficacy for treating dependency among persons seeking addiction treatment. However, effectiveness out-of-treatment, hospitalized patients is not known. To determine whether buprenorphine administration during medical hospitalization and linkage to office-based OAT after discharge increase entry into OAT, sustained engagement in decrease illicit use at 6 months hospitalization. From August 1, 2009, through October 31, 2012, a total...

10.1001/jamainternmed.2014.2556 article EN JAMA Internal Medicine 2014-07-01

Injection drug use is the primary mode of transmission for hepatitis C virus (HCV) infection. Prior studies suggest opioid agonist therapy may reduce incidence HCV infection among injection users; however, little known about effects this in younger users.To evaluate whether was associated with a lower cohort young adult users.Observational study conducted from January 3, 2000, through August 21, 2013, quarterly interviews and blood sampling. We recruited (younger than 30 years) users who...

10.1001/jamainternmed.2014.5416 article EN JAMA Internal Medicine 2014-10-27

Background: Infection with chronic hepatitis C virus (HCV) has been linked to glomerulonephritis.We undertook this study determine whether having a positive HCV test result was associated an increased risk for developing treated end-stage renal disease (ESRD).Methods: Using data from Medicare, the Department of Veterans Affairs, and United States Renal Data System, we performed retrospective cohort 474 369 adult veterans who had serum creatinine levels measured between October 1, 2000,...

10.1001/archinte.167.12.1271 article EN Archives of Internal Medicine 2007-06-25

This study examined associations between mortality and demographic risk characteristics among young injection drug users in San Francisco, California, compared the rate with that of population. A total 644 (<30 years) completed a baseline interview were enrolled prospective cohort study, known as UFO ("U Find Out") Study, from November 1997 to December 2007. Using National Death Index, authors identified 38 deaths over 4,167 person-years follow-up, yielding 9.1 (95% confidence interval: 6.6,...

10.1093/aje/kwr318 article EN American Journal of Epidemiology 2012-01-06

To characterize and address the opioid crisis disproportionately impacting rural U.S. regions.The Rural Opioid Initiative (ROI) is a two-phase project to collect harmonize quantitative qualitative data develop tailored interventions use. The baseline survey from people who use drugs (PWUD) characterizes current epidemic (2018-2020) in eight geographically diverse regions.Among 3,084 PWUD, 92% reported ever injecting drugs, 86% using opioids (most often heroin) 74% methamphetamine get high...

10.1186/s13722-022-00322-5 article EN cc-by Addiction Science & Clinical Practice 2022-07-26

Importance Emergency department (ED)–initiated buprenorphine for the treatment of opioid use disorder (OUD) is underused. Objective To evaluate whether provision ED-initiated with referral OUD increased after implementation facilitation (IF), an educational and strategy. Design, Setting, Participants This multisite hybrid type 3 effectiveness-implementation nonrandomized trial compared grand rounds IF, pre-post 12-month baseline IF evaluation periods, at 4 academic EDs. The study was...

10.1001/jamanetworkopen.2023.5439 article EN cc-by-nc-nd JAMA Network Open 2023-04-05
Moonseong Heo Brianna L. Norton Irene Pericot‐Valverde Shruti H. Mehta Judith I. Tsui and 95 more Lynn E. Taylor Paula J. Lum Judith Feinberg Arthur Y. Kim Julia H. Arnsten Sophie Sprecht-Walsh Kimberly Page Alain H. Litwin Alain H. Litwin Moonseong Heo Moonseong Heo Moonseong Heo Irene Pericot‐Valverde Hagan Walker Ashley Coleman Shruti H. Mehta Courtney Borsuk Brian E. Dickerson Oluwaseun Falade‐Nwulia Michael Fingerhood Taryn Haselhuhn Angela Mason Juhi Moon Yngvild Olsen Vickie Walters Arthur Y. Kim Jillian M. Roche William A. Schmitt Virginia Lijewski Anita Pitts Syeda Raji Taniya Silva F. Evans Hope Koene Joelle Brown Brianna L. Norton Linda Agyemang Julia H. Arnsten Alison Karasz Paul Meißner Kiara Lora Jennifer Hidalgo Irene Soloway Karen Jefferson Joyce Wong Andrea Kermack Melissa Stein Gilian Joseph Karyn London Lincoln Allen Venecia Marte Tatiana Vera Romy Alvarez M. Diane McKee Paula J. Lum Ellen Stein Anne F. Luetkemeyer Caycee Cullen Gurjot Gill Hannah Tierney Scott Shapiro Soraya Azari Joanna Eveland Daniel Berrner Pauli Grey Jordan Akerley Kimberly Page Katherine Wagner Herbert Davis Alain H. Litwin Vanessa Jacobsohn Alain H. Litwin Lynn E. Taylor Karen T. Tashima Sophie Sprecht-Walsh Aurielle Thomas Melissa Hordes Danielle McGregor Patrick Duryea Kathryn Weenig Judith I. Tsui Kendra L. Blalock Hyang Nina Kim Meena S. Ramchandani Jocelyn James K. Michelle Peavy Paul Grekin Michael Ninburg Judith Feinberg Samuel T. Wilkinson Danielle Thomas Lacey Kelley Andrea Calkins Gabrielle Henry Alice Ashler

10.1016/j.jhep.2023.12.020 article EN Journal of Hepatology 2024-01-17

Abstract Background In recent years, stimulant use has increased among persons who opioids in the rural U.S., leading to high rates of overdose and death. We sought understand motivations contexts for a large, geographically diverse sample drugs (PWUD) settings. Methods conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states 65 counties. Content areas included general substance use, injection drug changes harm reduction practices. used an iterative...

10.1186/s12954-024-00986-z article EN cc-by Harm Reduction Journal 2024-04-01

Abstract Background Hepatitis C virus (HCV) is a leading cause of infectious disease death in the United States. Although highly effective direct-acting antiviral (DAA) regimens are well established, retreatment among people who inject drugs (PWID) has not been sufficiently studied. This study assessed DAA outcomes and associated factors. Methods We performed analyses longitudinal data from HERO Study, US-based multi-site pragmatic randomized trial conducted 8 states to evaluate...

10.1093/cid/ciaf082 article EN Clinical Infectious Diseases 2025-04-15

Previous research supports an association between hepatitis C virus (HCV) infection and glomerulonephritis. However, little is known about the HCV chronic kidney disease. The cross-sectional prevalent seropositivity albuminuria estimated GFR (eGFR), respectively, was examined among 15,029 participants in Third National Health Nutrition Examination Survey (NHANES III). In multivariate analysis, we noted age-dependent (adjusted odds ratios 95% confidence intervals 0.83, 0.39 to 1.75 for ages...

10.1681/asn.2005091006 article EN Journal of the American Society of Nephrology 2006-03-09

Abstract Background Accurate prevalence estimates of drug use and its harms are important to characterize burden develop interventions reduce negative health outcomes disparities. Lack a sampling frame for marginalized/stigmatized populations, including persons who drugs (PWUD) in rural settings, makes this challenging. Respondent-driven (RDS) is frequently used recruit PWUD. However, the validity RDS-generated population-level relies on assumptions that should be evaluated. Methods RDS was...

10.1186/s12874-024-02206-5 article EN cc-by BMC Medical Research Methodology 2024-04-23

IMPORTANCE Hepatitis C virus (HCV) reinfection after curative treatment remains a concern for people who inject drugs. OBJECTIVE To assess the incidence of HCV and associated risk factors. DESIGN, SETTING, AND PARTICIPANTS This cohort study is secondary analysis randomized clinical trial that was conducted across opioid programs community health centers in US between September 2016 August 2018. The current analyses were performed March 2022. People drugs achieved sustained virologic response...

10.1001/jamanetworkopen.2024.30024 article EN cc-by-nc-nd JAMA Network Open 2024-08-26

Background: Few studies have assessed associations between craving and subsequent opioid use. We prospectively evaluated the relative utility of two questionnaires to predict use among opioid-dependent patients in outpatient treatment. Method: Opioid-dependent (n = 147) initiating buprenorphine treatment were every weeks for 3 months. Craving was measured using the: (1) Desires Drug Questionnaire (DDQ) (2) Penn Alcohol-Craving Scale adapted (PCS). Multi-level logistic regression models...

10.3109/00952990.2013.848875 article EN The American Journal of Drug and Alcohol Abuse 2014-02-12

Buprenorphine effectively reduces opioid craving and illicit use. However, some patients may not take their medication as prescribed thus experience suboptimal outcomes. The study aim was to qualitatively explore buprenorphine adherence the acceptability of utilizing video directly observed therapy (VDOT) among providers in an office-based program. Clinical (physicians staff; n = 9) well (n 11) were recruited from treatment program at urban academic medical center northwestern United States....

10.1186/s13722-019-0139-3 article EN cc-by Addiction Science & Clinical Practice 2019-03-13

Most people with opioid use disorder (OUD) never receive treatment. Medication treatment of OUD in primary care is recommended as an approach to increase access care. The PRimary Care Opioid Use Disorders (PROUD) trial tests whether implementation a collaborative model (Massachusetts Model) using nurse manager (NCM) support medication increases and improves outcomes. Specifically, it care, compared usual the number days for (implementation objective) reduces acute health utilization...

10.1186/s13722-021-00218-w article EN cc-by Addiction Science & Clinical Practice 2021-01-31
Coming Soon ...